WO1999039677A1 - Appareil de rayonnement d'ondes ultrasoniques - Google Patents
Appareil de rayonnement d'ondes ultrasoniques Download PDFInfo
- Publication number
- WO1999039677A1 WO1999039677A1 PCT/JP1998/005032 JP9805032W WO9939677A1 WO 1999039677 A1 WO1999039677 A1 WO 1999039677A1 JP 9805032 W JP9805032 W JP 9805032W WO 9939677 A1 WO9939677 A1 WO 9939677A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasonic
- irradiation
- living body
- range
- ultrasonic wave
- Prior art date
Links
- 206010018910 Haemolysis Diseases 0.000 claims abstract description 28
- 230000008588 hemolysis Effects 0.000 claims abstract description 28
- 208000008589 Obesity Diseases 0.000 claims description 31
- 230000005540 biological transmission Effects 0.000 claims description 28
- 235000020824 obesity Nutrition 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000007822 coupling agent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 10
- 238000002604 ultrasonography Methods 0.000 claims description 10
- 230000001678 irradiating effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000003925 fat Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 230000000694 effects Effects 0.000 description 23
- 230000004130 lipolysis Effects 0.000 description 19
- 235000021588 free fatty acids Nutrition 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 14
- 210000001789 adipocyte Anatomy 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000003796 beauty Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 230000002889 sympathetic effect Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000006096 absorbing agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000011358 absorbing material Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003880 negative regulation of appetite Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000002649 leather substitute Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- ZFLBZHXQAMUEFS-KUHUBIRLSA-N methyl 2-[4-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-KUHUBIRLSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
Definitions
- the present invention belongs to the field of devices for reducing / preventing obesity and improving health / cosmetic obesity, and is used particularly as a medical device or a health / beauty device for eliminating obesity by applying ultrasonic irradiation.
- the present invention relates to an ultrasonic irradiation device. Background art
- the used ultrasonic frequency is 1 1 ⁇ ⁇ ⁇ ⁇ , and some display the drive electric input, but there is no display for the ultrasonic sound output.
- the frequency is 1 ⁇ to 10 ⁇ for medical use, and 1 MHZ for beauty.
- the irradiation acoustic power areal density (hereinafter sometimes abbreviated as power density) is less than 100 OmWZc m 'for continuous irradiation and 240 mWZc (SP TA) or less for pulsed irradiation.
- 1 5 0 0 ⁇ 2 0 0 0 mW / cm for a further small Ku thick muscles output is for beauty, thin muscle in 1 5 0 0 ⁇ 1 0 0 0 mWZ cm 2, face 5 0 0 mW / cm ', and 1 2 0 mW / cm 2 with a pulse irradiation of the face, is set to hit the one-half of the ultrasonic medical community views.
- the numerical value of the power density described in the literature is Both are understood to be electrical outputs. If the numerical value of the power density described in the literature is an electrical output, the electrical-to-acoustic conversion efficiency of the transducer is usually about 30%, so for example, the power density for thick muscles 150 to 200 mWZ cm 2 (electrical power) corresponds to an ultrasonic power of 500 to 700 mW cm 2 , which is consistent with the statement that it is one half of the opinion of the ultrasonic medical community.
- An object of the present invention is to clarify the effective frequency of ultrasonic waves for biolipolysis and the power density range of each frequency including safety, and to irradiate ultrasonic waves for decomposing body fat by safe and effective ultrasonic waves. It is to provide equipment. Disclosure of the invention
- Fat in the body is synthesized from glucose and fatty acids by the action of lipogenic enzymes in fat cells, and part of the fat is accumulated inside fat cells to form oil droplets.
- white fat cells In the case of humans, almost all adult fat cells are white fat cells, and hereinafter simply referred to as fat cells refer to white fat cells.
- Adipocytes are elongated cells with a length of about 20 im when formed, but they become spherical with the accumulation of fat and the internal oil droplets grow to a diameter of 100 m, sometimes reaching 200 m Sometimes. Fat accumulation, with the exception of childhood, is primarily due to the enlargement of individual cells rather than to an increase in fat cell numbers.
- the oil droplets In the grown fat cells, the oil droplets are wrapped in an aqueous cell solution, but the thickness of the cell solution is smaller than the diameter of the oil droplets.
- the cell fluid contains the endoplasmic reticulum, which contains a lipolytic enzyme called hormone-sensitive lipase (HSL), which breaks down fat into glycerol and fatty acids.
- HSL hormone-sensitive lipase
- Fat oil droplets are covered with a layer of molecular fluid called phospholipids that are protected from lipolysis by contact with lipase.
- a part of the phospholipid layer is lost by the action of lipolysis-promoting hormones such as epinephrine (adrenaline) secreted by the adrenal medulla and norepinephrine (noradrenaline) released from the sympathetic nerve terminals.
- lipolysis-promoting hormones such as epinephrine (adrenaline) secreted by the adrenal medulla and norepinephrine (noradrenaline) released from the sympathetic nerve terminals.
- the oil droplets come into direct contact with the degrading enzyme, and lipolysis starts. Fat is broken down into fatty acids and glycerol and goes out into the blood. Finally, it is burned by exercise, etc., and excreted into breath and urine as CO and H 2 O.
- irradiation of a living body with ultrasonic waves has effects such as promotion of enzyme reaction, emulsification, heating, expansion of capillary blood vessels, and promotion of metabolism.
- the sympathetic nerve endings are stimulated and fat such as norepinephrine (noradrenaline) is stimulated.
- fat such as norepinephrine (noradrenaline) is stimulated.
- Degradation-promoting hormone is released, or disturbance is generated in the phospholipid layer and the oil droplet itself, so that the oil droplet and the degrading enzyme can come into contact with each other, and the effect of decomposing fat in the living body can be obtained.
- an ultrasonic irradiation apparatus includes an ultrasonic generation unit that generates ultrasonic waves, and irradiates the ultrasonic waves generated by the ultrasonic generation units to a living body to generate fat in the living body.
- the ultrasonic waves generated by the ultrasonic wave generating means have a frequency in a range of 15 to 140 k ⁇ , and the ultrasonic waves are irradiated on a living body surface to be irradiated with the ultrasonic waves.
- sound power surface density is greater than 1 O mW / cm 2 in the range of frequencies 1 5 ⁇ 5 0 k H z, in the range that does not cause hemolysis in vivo, the range of frequency 5 0 ⁇ 1 4 0 k H z Is characterized by not causing hemolysis in vivo at 4 mW Z cm 2 or more, or being in a range below a safety standard value based on a mechanical index.
- the ultrasonic irradiation apparatus includes ultrasonic generating means for generating ultrasonic waves, and irradiates the ultrasonic waves generated by the ultrasonic generating means to a living body to remove fat in the living body.
- the ultrasonic wave generated by the ultrasonic wave generating means has a frequency in a range of 180 kHz to 1.3 MHz, and is applied to a surface of a living body irradiated with the ultrasonic wave.
- Irradiated sound power area density is greater than 10 mWZc in the frequency range of 180 to 700 kHz and less than the safety standard value based on the mechanical index, and the frequency is 700 kHz. ⁇ 800 mW / cm-in the range of l.3 MHz, below the safety standard based on the canal index It is characterized by being.
- the upper limit of the irradiation acoustic power-area density is set to a range that does not cause hemolysis or is less than a safety reference value based on a mechanical index.
- the upper limit is set to a range that does not cause hemolysis or is less than the safety standard value of the ultrasonic device for medical diagnosis.
- the safety reference value based on the mechanical index of the irradiation acoustic surface area density is such that, for each frequency, the mechanical index is The irradiation acoustic power area density is 0.6.
- the ultrasonic irradiation may be continuous irradiation, pulse irradiation, intermittent irradiation, or a combination thereof. Intermittent irradiation can separate the irradiation time of contact formation between the decomposing enzyme and the oil droplets from the decomposition time after contact.
- the transmittance decreases exponentially with the distance traveled in vivo.
- the exponent is the absorption coefficient X distance.
- the absorption coefficient further increases in proportion to the frequency. For example, the value obtained by dividing the fat absorption coefficient of the human body by the frequency is 0.063 nepa / cm cm / cm, and the attenuation rate when moving 1 cm through the fat layer at 1 MHz is 0. 5 5 dB / cm, and 1.09 dBZcm for muscles as well.
- the valid range 8 0 0 ⁇ 1 0 0 0 mW / c m '1 of 1 MH zeta, effective depth is equivalent to 1. 7 cm, muscle 0. 9 cm from the body in the fat.
- the MI standard should be considered applicable to the treatment of obesity and obesity-related diseases, and is a diagnostic device standard for diagnosis and health promotion including unspecified healthy persons, and for lipolysis for beauty.
- mWZ cm 2 or less should be used. Below about 1 MHz, which we predict the biochemical effect of obesity elimination, the absorption coefficient is proportional to the frequency, so the permeability is large and the biochemical effect is also considered to be strong. Therefore, even when Ml is 0.6 or less, the effects on bones, blood vessels, and internal organs must be carefully considered.
- cavitation predominant below 100 kHz has a risk of destroying cells, and gives a feeling of tingling and discomfort even at a strength that does not destroy cells.
- Hemolysis occurs when a large emulsifying / dispersing force acts on red blood cells in blood. These effects are also a function of the frequency and the power density, and need to be within a range that does not cause the hemolysis.
- the World Federation of Ultrasound Medicine states that the temperature of tissue due to the heating effect should be noted for a wide range of uses, including therapeutic uses other than diagnostics. It is used. A temperature rise of 1.5 ° C or less is considered to be safe, 4 ° C for 5 minutes, and 2 ° C for 30 minutes requires caution.
- the ultrasonic irradiation apparatus of the present invention includes monitoring means for monitoring the position or the temperature of the part to be irradiated with the ultrasonic wave.
- the ultrasonic irradiation device of the present invention has a monitoring means.
- the ultrasonic irradiation device of the present invention includes an ultrasonic transmission unit that transmits an ultrasonic wave generated by the ultrasonic generation unit to a living body via an ultrasonic transmission medium.
- the ultrasonic transmission medium include water, a bag-like body containing water / liquid, a solid acoustic coupler, and the like.
- a bathtub or a water tank provided with the ultrasonic generation means and containing an ultrasonic transmission medium such as water; the ultrasonic generation means; a bag-like body containing water and liquid;
- An ultrasonic probe made of an ultrasonic transmission medium such as a solid acoustic coupler can be used.
- the ultrasonic transmission means includes an acoustic binder layer provided between the ultrasonic transmission medium and a living body.
- an ultrasonic irradiation device provided with an ultrasonic transmission means such as the ultrasonic probe
- the ultrasonic waves are reflected by the air layer, Ultrasonic waves radiated to the air are reduced. Therefore, by interposing an acoustic binder layer between the ultrasonic transmission medium and the living body, attenuation of the ultrasonic waves can be reduced and the living bodies can be efficiently irradiated with the ultrasonic waves.
- the acoustic coupling agent may be any as long as it can remove air from between the ultrasonic transmission medium and the living body, and examples thereof include jelly-like and cream-like substances.
- the acoustic coupling agent may contain an obesity eliminating agent.
- Percutaneous application for obesity elimination A substance that has both an obesity elimination function and a good acoustic coupling function by including a drug as a part of the acoustic binder or as a substitute for the acoustic binder itself. Can be provided.
- the acoustic binder including an obesity-relieving agent can produce a synergistic effect in combination with ultrasonic irradiation.
- the ultrasonic irradiation device of the present invention may include a unit for applying the liquid to which the ultrasonic wave generated by the ultrasonic wave generating unit is applied to a living body.
- a unit for applying the liquid to which the ultrasonic wave generated by the ultrasonic wave generating unit is applied to a living body for example, water, a shower head provided with the ultrasonic wave generating means, 0 While applying hot water or the like, ultrasonic waves may be applied to the water, hot water, or the like from the ultrasonic wave generating means, and the water, hot water, or the like may be jetted from the shower head to a living body.
- An ultrasonic wave generating means may be provided, in which warm water or the like to which ultrasonic waves are applied is circulated through the bath to hit the living body. According to such an ultrasonic irradiation apparatus, the ultrasonic irradiation can be performed safely and comfortably with no operation and with easy operation.
- lipolysis products such as free fatty acids that have been lipolyzed in the above processes are released into the blood, exercise, exercise of body temperature, etc. must be performed in order to prevent re-synthesis and accumulation of fat in the body. Need to burn and consume.
- the ultrasonic irradiation device of the present invention may include an obesity-relieving agent to be administered to a living body when the living body is irradiated with the ultrasonic wave generated by the ultrasonic wave generating means.
- the obesity relieving agent may be administered transdermally, orally, or may be administered by injection.
- increase heat metabolism such as pepper
- drugs such as capsaicin and its analogs such as pepper, sibutramine
- free fatty acids burn in the body and the body temperature increases for a long time. rise and the external dissipation of body heat increases. This consumes lipolysis products such as free fatty acids.
- a synergistic effect can be obtained by performing the ultrasonic irradiation of the present invention while administering the obesity-relieving agent.
- an obesity-relieving agent prevents the transfer and accumulation of fat from another portion again in a portion degraded by local irradiation, and an effect such as local thinning can be obtained by the synergistic action of the obesity-relieving agent and ultrasonic irradiation.
- the ultrasonic irradiation apparatus of the present invention may include a cooling unit that cools at least a part of a living body.
- a cooling unit that cools at least a part of a living body.
- body heat is deprived, and as a living body's autonomous action, a constant temperature animal produces heat and consumes free fatty acids. That is, the consumption of the free fatty acid proceeds simultaneously with the ultrasonic irradiation.
- the cooling means may be, for example, a means for cooling the ultrasonic transmission medium and bringing the medium into contact with a living body. If a means for controlling the temperature of the ultrasonic transmission medium to a temperature lower than the body temperature, for example, 24 ° C., is provided, body heat is deprived through the contact surface, and as a result of the autonomous action of the living body, a constant temperature animal produces heat. I do. BRIEF DESCRIPTION OF THE FIGURES n
- Figure 1 is an explanatory cross-sectional view of an experimental apparatus used in an experiment to determine the range of ultrasonic frequencies in the present invention, a range of illumination sound power surface density at each frequency.
- FIG. 2 is a double logarithmic graph showing the effective range of the ultrasonic frequency and the irradiation acoustic power areal density in the present invention.
- t 4 is an explanatory sectional view showing a first embodiment of an ultrasonic irradiation apparatus of the present invention, in an illustrative cross-sectional view showing a second embodiment of an ultrasonic irradiation apparatus of the present invention
- FIG. 5 is an explanatory sectional view showing a third embodiment of the ultrasonic irradiation apparatus of the present invention.
- FIG. 6 is an explanatory view showing a modification of the third embodiment of the ultrasonic irradiation apparatus of the present invention. It is sectional drawing.
- FIG. 7 is an explanatory sectional view showing a fourth embodiment of the ultrasonic irradiation apparatus of the present invention.
- FIG. 8 is an explanatory cross-sectional view showing a fifth embodiment of the ultrasonic irradiation apparatus of the present invention.
- the present inventors first investigated the critical power densities of hemolysis, cavitation, cell destruction, and emulsification by experiments in order to confirm safety.
- the available frequency range is 0.8 MHz or more by the balance method for slightly available equipment, but the cause is the low frequency range.
- the measurement was performed with a continuous wave of six frequencies of 24 kHz, 36 kHz, 100 kHz, 160 kHz, 500 kHz, and 1 MHz.
- FIG. 1 shows an experimental apparatus used for the above-described experiments such as hemolysis, in which a guide member 3 provided above a water tank 2 containing hot water 1 as an ultrasonic transmission medium is made of a box made of a material that transmits ultrasonic waves.
- a sample holder 4 having a rectangular shape and a slider 6 having an ultrasonic vibrator device 5 movably up and down are provided.
- the sample holder 4 and the ultrasonic transducer device 5 are movable along the guide member 3 by supporting beams 4a and 6a, respectively, so that the sample held by the sample holder 4 is Adjustment is made so that the ultrasonic wave emitted from the ultrasonic transducer device 5 is located within a long-range sound field.
- the hemolysis test was performed by collecting venous blood, adding heparin to prevent coagulation, and refrigerated. 1 ml was placed in a 20 micron thick bag of polyethylene, immersed in the water shown in Fig. 1 at 36 ° C with hot water 1 at 36 ° C, and irradiated for 30 minutes under each test condition (frequency and power density). . Immediately after the irradiation, centrifugation was performed, and colorimetry of serum and LDH (lactate dehydrogenase) separation were performed.
- LDH lactate dehydrogenase
- Hemolysis has a threshold for power density (hereinafter referred to as the hemolysis limit). It was confirmed that hemolysis was safe below this threshold and that hemolysis was above.
- Table 1 shows the measured hemolysis threshold.
- Figure 2 shows the points on curve A.
- the cavitation limit of power density ⁇ The emulsification limit is larger than the hemolysis limit, and it is sufficient to pay attention to the hemolysis limit. Adipocytes breakdown limit further increases were not observed in l OO OmWZc m 2 or less.
- the hemolysis limit is determined
- the acceptable level for diagnosis by the Japanese Society of Ultrasonics is less than 100 mWZ cm continuous wave.
- WF UMB MI 0.6 or less (line G in Fig. 2).
- the central nervous system was anesthetized with Nembutal, and the effects of psychological stress, blood sampling pain, and the effects of low frequency ultrasound on the rat were cut off.
- the abdominal body hair was cut off and washed with a surfactant because there was a risk of leaving air bubbles that hindered ultrasonic transmission.
- a t-test was performed on b at each measurement point in comparison with b in the control.
- the value of the multiplication factor b is shown for each point.
- each frequency has a lower threshold for the effective power density, which is valid above the threshold and invalid below. (The threshold is hereinafter referred to as the effective lower limit.)
- the effective lower limit is hereinafter referred to as the effective lower limit.
- the effective lower limit is 10 mWZ cm at the high range of 500 kHz
- the effective area surrounded by the boundary line connecting the threshold values is determined from the night in FIG.
- the display of the measurement points in the figure has the following meaning.
- ⁇ is completely within the effective area and far from the boundary.
- Ginseng is completely within the dead zone and far from the border.
- ⁇ is almost on or near the boundary line.
- ⁇ is close to the boundary line but within the invalid area.
- the upper limit is 1.3 MHz, which is the frequency at which the effective depth disappears with lWZ cm 2 of body surface irradiation.
- higher frequencies can be used at high power densities, but the power absorption coefficient is proportional to twice the frequency, increasing heat generation and exceeding the thermal index. There are excluded.
- the lower limit is set to 800 mWZ cm 2 and the upper limit is set to the MI allowable value between 700 kHz and 1.3 MHz.
- a boundary line is 50 kHz, which is close to 6 kHz.
- the area is surrounded by the boundary ABCDFG, and in the ultrasonic irradiation apparatus according to the second embodiment, the area is surrounded by the boundary GHIJKL.
- the sound pressure absorption coefficient is proportional to When the power density at the body surface is increased to maintain the degree, the ultrasonic absorption energy per lcm depth (proportional to the square of the sound pressure) is proportional to twice the frequency, so the absorbed heat per lcm And there is a risk that the temperature rise near the body surface will exceed the thermal index.
- the band from 15 kHz to 140 kHz has a low absorption coefficient by living tissue and can reach deep into the body, so it is effective in decomposing not only subcutaneous fat but also visceral fat that causes adult diseases.
- the 180 MHz to 1.3 MHz band has the same effectiveness over a wide range of 100 to 100 mWZ cm at an effective power density of, for example, 500 kHz. That is, it is suitable for lipolysis in a wide range from shallow subcutaneous fat to deep visceral fat. Moreover, since the power density is attenuated in the deep part, there is an advantage that the effect on the internal organs and bones is completely ignored.
- the ultrasonic irradiation apparatus shown in FIG. 3 includes a bathtub 2 in which hot water 1 is stored, and an ultrasonic vibrator 5 attached to a wall surface of the bathtub 2 as ultrasonic generating means.
- the ultrasonic oscillator 5 generates an ultrasonic wave by applying a high-frequency voltage supplied from a drive circuit (not shown), and irradiates the ultrasonic wave to the living body 9 immersed in the bathtub 2 via the warm water 1. You.
- a drive circuit not shown
- the ultrasonic irradiation device shown in FIG. 4 has a water tank 10 containing hot water 1 and a water tank 10 1 ⁇
- the living body 9 contacts the hot water 1 using the sponge 11 provided at the upper part of the water tank 10 as an elastic sealing material.
- a conduit 12 for supplying hot water 1 to the water tank 10 at a constant pressure is connected to the bottom of the water tank 10.
- the warm water 1 supplied to the water tank 10 from 12 is overflowed from the sponge 11 through an overflow pipe (not shown) or the overflow tank provided on the outer wall of the water tank 10.
- the ultrasonic vibrator 5 generates ultrasonic waves by the same mechanism as the ultrasonic vibrator 5 shown in FIG. 3, and irradiates the ultrasonic waves to the living body 9 via the warm water 1.
- the abdomen and the like can be brought into contact with water without leaving air on the open water surface of the water tank 10.
- the conventional actual irradiation method is a method in which a small vibrator is brought into contact with the body surface via the jelly of the acoustic coupling agent to scan the body surface in a planar manner.
- the near-field has a non-uniform intensity distribution due to interference, so the spatial averaging of the irradiation dose is obtained by planar scanning, which is an appropriate method.
- this method requires caution when there is a very clear limit value such as the hemolysis described above. That is, physiological phenomena jump non-linearly at the limit value, and there is a danger if the local value exceeds the limit value even if the average value is below the safe value.
- the ultrasonic irradiation device shown in FIG. 5 (a) has an ultrasonic vibrator 5 inside a hollow applicator 15, an acoustic lens 16 provided on the front surface of the ultrasonic vibrator 5, and a polyethylene or the like. And a bag 17 made of a flexible film.
- the bag 17 contains a liquid 18 such as water and oil as an ultrasonic transmission medium.
- the ultrasonic transducer 5 is the ultrasonic wave shown in Fig. 3. Ultrasonic waves are generated by the same mechanism as that of the ⁇ vibrator 5, and the living body 9 is irradiated with ultrasonic waves via the liquid 18 and the like contained in the bag-like body 17.
- the acoustic lens 16 is a sound-transmitting solid, the upper surface of which is in close contact with the ultrasonic vibrator 5 and the lower surface has a concave shape.
- the material of the acoustic lens 16 is faster than the ultrasonic transmission medium 18. Due to the refraction between the ultrasonic transmission medium 6 and the ultrasonic transmission medium 18, the ultrasonic waves are formed in a substantially parallel beam shape. The concave curvature may be increased to form a convergent beam. In this case, the same effect as that of the irradiation applicator 23 of FIG. 6 (c) described later can be obtained.
- the bag-like body 17 and the ultrasonic transmission medium 18 such as water contained in the bag-like body 17 are deformed according to the unevenness of the surface of the living body 9 and adhere to the living body 9.
- An acoustic coupling agent (not shown) (jelly or the like) is applied to the contact surface between the bag 17 and the living body 9 to eliminate air.
- the ultrasonic irradiation applicator shown in Fig. 5 (a) can be used in the air without using a tank, and can be slid along the living body 9, so it is for local irradiation and has a relatively wide irradiation field. Can be designed.
- the acoustic coupling agent may include a transdermally administrable obesity eliminating agent such as capsaicin.
- a transdermal administration agent for obesity-eliminating such as cabsaicin
- a cream-like agent can eliminate an air layer between the bag-like body 17 and the living body 9, so that acoustic impedance is reduced.
- it can itself be used as an acoustic coupling agent.
- an obesity eliminating agent can be mixed with the acoustic coupling agent, or a new acoustic coupling agent having an obesity eliminating function and having an acoustic impedance close to an ideal value and optimized can be used.
- the ultrasonic irradiation device shown in FIG. 5A may include a belt 20 made of synthetic resin or leather on the upper part of the applicator 15.
- the user can operate by inserting his hand into the gap 21 between the applicator 15 and the belt 20, and the handling becomes easy.
- the ultrasonic irradiation applicator shown in Fig. 5 (a) shows the frequency, power density, ie
- a part of the ultrasonic transducer 5 may be cut off in the applicator 15 and the ultrasonic pulse transmitting / receiving transducer 22 may be provided.
- Fig. 6 (a) shows an example in which the center of the ultrasonic transducer 5 is cut out and the ultrasonic pulse transmitting and receiving transducer 22 is provided
- Fig. 6 (b) shows an example in which the end of the ultrasonic transducer 5 is cut out.
- the ultrasonic pulse transmitting / receiving oscillator 22 in the applicator 15 shown in FIGS. 6 (a) and 6 (b) should be fan-shaped and linear-scanned as in the conventional B-mode ultrasonic echo imager. Can be.
- Reception time which is the physical constant of the reflected wave from each part in the living body, and imaging of the scanning cross section by measuring the reception intensity, and changes in the sound speed and absorption temperature due to changes in the reception time and intensity of the reflected wave from a specific part It is also possible to know the location of the irradiation site and monitor the temperature rise due to irradiation.
- the attenuation rate of the sound wave of fat fluctuates relatively greatly with temperature, for example, by penetrating the irradiated site by applying the principle that the attenuation rate decreases by about 10% for every 1 ° C increase near 20 or
- the change in the intensity of the reflected ultrasound with that at the start of irradiation, it is possible to control the irradiation conditions based on the estimation of the temperature rise of the living body.
- the irradiation applicator 23 having the ultrasonic pulse transmitting / receiving vibrator 22 is provided independently, and the position, structure, Temperature and the like can be monitored.
- the vibrator can be switched over in time to double as a pulse transmitting / receiving vibrator.
- the ultrasonic waves are crossed by the ultrasonic transducers 5 of the plurality of applicators 15 at a crossing angle of 0, and interference or synthesis is performed so that only the specific irradiation area is obtained. And the intensity of irradiation can be increased.
- a plurality of different body surface positions are focused on a specific site to irradiate them in a focused manner.
- the required irradiation intensity can be concentrated on a specific part in a deep part while keeping the vicinity at a safe irradiation intensity or less. Irradiation from one place requires a large intensity on the body surface to overcome the attenuation on the way, and solves the problem of excessive intensity near the body surface. In particular, it is effective when deep irradiation is performed at a frequency having a large absorption coefficient such as 1 to 1.3 MHz.
- the frequency of the irradiation wave When the frequency of the irradiation wave is low, the reaching distance in the living body increases. On the other hand, when the frequency is high, the attenuation increases. In the low range, macroscopic deformation, disturbance, and flow of the oil droplets and the phospholipid membrane that surrounds it occur, and in the high range, hormone release due to sympathetic stimulation, microdisturbance and fluidization of the phospholipid membrane and sympathetic nerve terminal membrane Is supposed to occur. Although these characteristics have not been demonstrated, they are considered to have different effects.
- a plurality of transducers are provided in the same device, and the living body can be irradiated with ultrasonic waves having different frequencies alternately or simultaneously. The frequency may be switched by replacing the vibrator.
- the ultrasonic irradiation applicator shown in FIG. 7 has an ultrasonic vibrator 5 attached to the tip of a grip portion 24 at an appropriate angle via a backing material 25, and is provided on the front surface of the ultrasonic vibrator 5.
- Hard acoustic coupler 26 is provided.
- the ultrasonic irradiation applicator shown in FIG. 7 can be irradiated by moving and scanning a specific area in direct contact with the surface of a living body 9 coated with an acoustic binder (jelly or the like). Suitable for high frequency of about 500 kHz, which is a small vibrator.
- the tip of the L-shaped grip 24 is strongly pressed against the body surface, the body surface shape is changed, and the subcutaneous fat layer is irradiated. It is possible to irradiate the position with emphasis. 9 is the human skin and 27 is the fat layer.
- the ultrasonic irradiation applicator shown in Fig. 7 (a) is used when irradiating a part with a lot of subcutaneous fat such as the buttocks, and is characterized by a hard sound at the tip of the grip part 24 on the skin and fat layer of the human body.
- the coupler 26 By strongly pressing the coupler 26, the skin 9 and a part of the fat layer 27 are deformed into a concave shape, and the concave portion is dented as shown in Fig. 7 (a). Ultrasonic waves are emitted from the ultrasonic oscillator 5. For this reason, the grip 24 and the irradiation direction of the ultrasonic transducer 5 are set to be at right angles.
- an acoustic coupler 26 is provided between the concave ultrasonic transducer 5 and the skin 9 to improve the close contact with the human body 9 to enhance operability, and a jelly-like shape is provided between the skin 9 and the acoustic coupler 26.
- the grip portion 24 may be a straight rod shape as shown in FIG. 7 (b), or may extend obliquely upward from the back member 25 as shown in FIG. 7 (c). .
- the shape of the grip portion 24 can be appropriately selected depending on the region to be irradiated with the ultrasonic wave or according to the user's preference.
- the ultrasonic irradiation device shown in FIG. 8 has an ultrasonic vibrator 5 mounted inside a shower head 28, and water (or hot water) 30 circulated through the shower head 28 by a hose 29. Then, an ultrasonic wave is applied from the ultrasonic transducer 5.
- the water (or warm water) 30 to which the ultrasonic waves are applied is ejected from a large number of small holes 31 formed in the surface of the shower head 28 facing the ultrasonic transducer 5, and is applied to a living body (not shown). Is received.
- an ultrasonic wave can be easily applied to an arbitrary site by pouring the jet stream into a site to be irradiated, for example, an abdomen or a lower leg.
- the water may be jetted out as one or a plurality of large-diameter water streams without providing the small holes 31.
- Fat decomposition products produced by ultrasonic lipolysis using the ultrasonic irradiation apparatus of each of the above embodiments are partially synthesized again into fat and accumulated in fat cells unless burned. Therefore, it is necessary to burn and consume FFA for exercise and dietary control. Therefore, an effective synergistic effect can be expected by irradiating the living body with ultrasonic waves while using an anti-obesity agent in combination.
- the portion decomposed by lipolysis by local irradiation has the effect of preventing the migration and accumulation of fat from other portions again, and can achieve local thinning, which is a large cosmetic effect.
- Such drugs have been variously studied.
- the main components are appetite suppressants, digestion and absorption suppression, energy expenditure enhancers, and the aforementioned heat metabolism enhancers.
- appetite suppressants are appetite suppressants, digestion and absorption suppression, energy expenditure enhancers, and the aforementioned heat metabolism enhancers.
- hormones that aim to promote lipolysis and suppress fat synthesis Cat echo lamine, norepinephrine, dexfenfluramine, dopamine, serotonin for central nervous system appetite suppression, amphetamine, mazindol for suture control, and s ibutramine, a heat metabolism enhancer as described above, which combines appetite suppression and heat metabolism promotion Orlistat is known as a digestive absorption inhibitor.
- thermometabolic agents are particularly effective to use the administration of foods and drugs that enhance thermal metabolism and increase body temperature in combination with ultrasonic irradiation.
- This rise in body temperature is caused by the burning of free fatty acids, which increases the dissipation of body heat and burns and consumes lipolysis products.
- cooling means should be provided to burn and consume FFA by immersing at least a part of the living body, for example, hands and feet, in a nearby warm water bath with 24, or exposing it to a shower near that temperature. Can be.
- the cooling time may be after or after irradiation.
- the ultrasonic transmission medium 18 shown in FIGS. 5 and 6 can be used after being cooled, and the warm water 1 and the water bath 5 contained in the bath 2 shown in FIG. 3 or the water tank 5 shown in FIG.
- Means for controlling the liquid temperature of the warm water 30 in FIG. 8 to a temperature lower than the body temperature, for example, 24 to 29 ° C., may be provided. Controlling the temperature is achieved by connecting the simmering hot water in the thermostatic bath to the bathtub 2 in Fig. 3, the water bath 5 in Fig. 4, the bag 17 in Figs. it can. Body heat is deprived through the contact surface, and in a constant-temperature animal, heat is produced by autonomous action of the living body and FFA is consumed. In other words, the FFA consumption at the same time proceed.
- the reflection is similarly performed by combining a reflector instead of the transducer.
- the transmission frequency, intensity, and phase can be changed to control the position, number, and intensity of the standing wave.
- the variable frequency range can easily realize 10% of the center frequency.
- the irradiation range can be limited by controlling the standing wave. It can be realized by appropriately providing not only a reflector but also an absorber having an appropriate shape such as an ultrasonic absorber such as a mixture of heavy particles and a viscous material.
- the frequency, intensity, and phase can be changed over time, and the effect of sweeping the irradiation field and averaging the local unevenness over time can be expected.
- the apparatus which irradiates an ultrasonic wave to a living fat cell and performs a body fat decomposition
- this device creates a new large-scale industry and has great industrial applicability.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Surgical Instruments (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002319583A CA2319583C (en) | 1998-02-05 | 1998-11-09 | Ultrasound sonication equipment |
US09/600,177 US6450979B1 (en) | 1998-02-05 | 1998-11-09 | Ultrasonic wave irradiation apparatus |
AU97629/98A AU9762998A (en) | 1998-02-05 | 1998-11-09 | Ultrasonic wave irradiation apparatus |
EP98951740A EP1060728B9 (en) | 1998-02-05 | 1998-11-09 | Ultrasonic wave irradiation apparatus and non-therapeutic method of treatment |
BRPI9815088-0A BR9815088B1 (pt) | 1998-02-05 | 1998-11-09 | equipamento de sonificaÇço de ultra-som. |
JP2000530179A JP3416909B2 (ja) | 1998-02-05 | 1998-11-09 | 超音波照射装置 |
DE69841275T DE69841275D1 (de) | 1998-02-05 | 1998-11-09 | Bestrahlungsvorrichtung mit ultraschallwellen, sowie nicht-therapeutisches behandlungsverfahren |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPPCT/JP98/00487 | 1998-02-05 | ||
PCT/JP1998/000487 WO1998053787A1 (fr) | 1997-05-26 | 1998-02-05 | Agent de decomposition du tissu adipeux utilisant des ondes ultra sonores |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999039677A1 true WO1999039677A1 (fr) | 1999-08-12 |
Family
ID=14207562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/005032 WO1999039677A1 (fr) | 1998-02-05 | 1998-11-09 | Appareil de rayonnement d'ondes ultrasoniques |
Country Status (10)
Country | Link |
---|---|
US (1) | US6450979B1 (ja) |
EP (1) | EP1060728B9 (ja) |
JP (1) | JP3416909B2 (ja) |
CN (1) | CN1163211C (ja) |
AU (1) | AU9762998A (ja) |
BR (1) | BR9815088B1 (ja) |
CA (1) | CA2319583C (ja) |
DE (1) | DE69841275D1 (ja) |
ES (1) | ES2335826T3 (ja) |
WO (1) | WO1999039677A1 (ja) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003533263A (ja) * | 1997-10-27 | 2003-11-11 | ロバート ダブリュー クリブス | 脂肪分解療法及び装置 |
WO2004058135A1 (ja) * | 2002-12-24 | 2004-07-15 | Matsushita Electric Works, Ltd. | 超音波痩身装置 |
KR100443201B1 (ko) * | 2001-12-10 | 2004-08-09 | 주식회사 울쏘하이텍 | 비데의 노즐장치 |
WO2007013546A1 (ja) * | 2005-07-29 | 2007-02-01 | Kabushiki Kaisha Shunkosha | 痩身促進具 |
JP2008529580A (ja) * | 2005-02-06 | 2008-08-07 | ウルトラシェイプ エルティーディー. | 非熱式音波組織改質 |
JP2010535060A (ja) * | 2007-07-30 | 2010-11-18 | リゼンプライム カンパニー リミテッド | むくみ治療用超音波装置およびその用途 |
JP2017077310A (ja) * | 2015-10-20 | 2017-04-27 | 株式会社ジャパンギャルズ | 超音波美容器 |
JP2018108523A (ja) * | 2004-10-06 | 2018-07-12 | ガイデッド セラピー システムズ, エル.エル.シー. | 超音波組織処理ための方法およびシステム |
US10525288B2 (en) | 2004-10-06 | 2020-01-07 | Guided Therapy Systems, Llc | System and method for noninvasive skin tightening |
US10532230B2 (en) | 2004-10-06 | 2020-01-14 | Guided Therapy Systems, Llc | Methods for face and neck lifts |
US10537304B2 (en) | 2008-06-06 | 2020-01-21 | Ulthera, Inc. | Hand wand for ultrasonic cosmetic treatment and imaging |
JP2020044303A (ja) * | 2018-09-14 | 2020-03-26 | 昌利 神尾 | 血管内皮機能改善法及びこれに使用する血管内皮機能改善具 |
US10603523B2 (en) | 2004-10-06 | 2020-03-31 | Guided Therapy Systems, Llc | Ultrasound probe for tissue treatment |
US10603521B2 (en) | 2014-04-18 | 2020-03-31 | Ulthera, Inc. | Band transducer ultrasound therapy |
US10603519B2 (en) | 2004-10-06 | 2020-03-31 | Guided Therapy Systems, Llc | Energy based fat reduction |
US10610705B2 (en) | 2004-10-06 | 2020-04-07 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US10610706B2 (en) | 2004-10-06 | 2020-04-07 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US10864385B2 (en) | 2004-09-24 | 2020-12-15 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
US10960235B2 (en) | 2004-10-06 | 2021-03-30 | Guided Therapy Systems, Llc | Energy based hyperhidrosis treatment |
US11207548B2 (en) | 2004-10-07 | 2021-12-28 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US11224895B2 (en) | 2016-01-18 | 2022-01-18 | Ulthera, Inc. | Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof |
US11235179B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | Energy based skin gland treatment |
US11241218B2 (en) | 2016-08-16 | 2022-02-08 | Ulthera, Inc. | Systems and methods for cosmetic ultrasound treatment of skin |
US11338156B2 (en) | 2004-10-06 | 2022-05-24 | Guided Therapy Systems, Llc | Noninvasive tissue tightening system |
US11517772B2 (en) | 2013-03-08 | 2022-12-06 | Ulthera, Inc. | Devices and methods for multi-focus ultrasound therapy |
US11724133B2 (en) | 2004-10-07 | 2023-08-15 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US11883688B2 (en) | 2004-10-06 | 2024-01-30 | Guided Therapy Systems, Llc | Energy based fat reduction |
RU2815510C1 (ru) * | 2023-05-25 | 2024-03-18 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт прикладной акустики" | Устройство для гидровиброакустического массажа |
US11944849B2 (en) | 2018-02-20 | 2024-04-02 | Ulthera, Inc. | Systems and methods for combined cosmetic treatment of cellulite with ultrasound |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020004562A (ko) * | 2000-07-06 | 2002-01-16 | 강원석 | 초음파를 이용한 샤워기 |
NO315547B1 (no) | 2000-10-16 | 2003-09-22 | Meditron Asa | Medisinsk plaster |
DE60134177D1 (de) * | 2001-01-03 | 2008-07-03 | Ultrashape Inc | Eingriffsfreie ultraschall körperkonturierung |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
GB0111440D0 (en) * | 2001-05-10 | 2001-07-04 | Procter & Gamble | Method and kit for the treatment or prevention of cosmetic skin conditions |
US6646903B2 (en) * | 2001-12-03 | 2003-11-11 | Intel Corporation | Ferroelectric memory input/output apparatus |
KR100923717B1 (ko) | 2002-06-25 | 2009-10-27 | 울트라세이프 인코포레이티드 | 신체 미용에 유용한 디바이스 및 방법 |
AT412255B (de) * | 2003-01-22 | 2004-12-27 | Luttermann Joachim | Vorrichtung zur harmonisierung von natürlichen schwingungen des menschlichen körpers |
KR100537343B1 (ko) * | 2004-10-01 | 2005-12-19 | 주식회사 듀플로젠 | 관절염 치료용 초음파 장치 |
US7815581B1 (en) | 2005-01-05 | 2010-10-19 | Chien-Min Sung | Cellular exercise method |
US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9358033B2 (en) | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
US7967763B2 (en) * | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US20070060989A1 (en) * | 2005-09-07 | 2007-03-15 | Deem Mark E | Apparatus and method for disrupting subcutaneous structures |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US10548659B2 (en) | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
US7885793B2 (en) | 2007-05-22 | 2011-02-08 | International Business Machines Corporation | Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution |
US9248317B2 (en) | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US9107798B2 (en) * | 2006-03-09 | 2015-08-18 | Slender Medical Ltd. | Method and system for lipolysis and body contouring |
US20090048514A1 (en) * | 2006-03-09 | 2009-02-19 | Slender Medical Ltd. | Device for ultrasound monitored tissue treatment |
US7828734B2 (en) * | 2006-03-09 | 2010-11-09 | Slender Medical Ltd. | Device for ultrasound monitored tissue treatment |
WO2008077096A2 (en) * | 2006-12-19 | 2008-06-26 | Cedars-Sinai Medical Center | Ultrasonic bath to increase tissue perfusion |
US20100094179A1 (en) * | 2006-12-22 | 2010-04-15 | Smith & Nephew Inc | Optimized Diffraction Zone for Ultrasound Therapy |
ITRM20070148A1 (it) * | 2007-03-21 | 2008-09-22 | Giancarlo Millevolte | Dispositivo per la produzione di ultrasuoni a bassa frequenza per il trattamento della cellulite e di adiposita localizzate |
US20090062724A1 (en) * | 2007-08-31 | 2009-03-05 | Rixen Chen | System and apparatus for sonodynamic therapy |
US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
WO2009050719A2 (en) * | 2007-10-15 | 2009-04-23 | Slender Medical, Ltd. | Implosion techniques for ultrasound |
US8579835B2 (en) * | 2008-02-01 | 2013-11-12 | Alma Lasers Ltd. | Apparatus and method for selective ultrasonic damage of adipocytes |
WO2010029555A1 (en) * | 2008-09-12 | 2010-03-18 | Slender Medical, Ltd. | Virtual ultrasonic scissors |
US20100280419A1 (en) * | 2009-05-01 | 2010-11-04 | Dimitri Donskoy | Ultrasonically Assisted Fitness Method and Apparatus |
US8292835B1 (en) | 2009-05-01 | 2012-10-23 | Body Beam Research Inc. | Non-invasive ultrasonic soft-tissue treatment method |
US20100286519A1 (en) * | 2009-05-11 | 2010-11-11 | General Electric Company | Ultrasound system and method to automatically identify and treat adipose tissue |
US20100286518A1 (en) * | 2009-05-11 | 2010-11-11 | General Electric Company | Ultrasound system and method to deliver therapy based on user defined treatment spaces |
US20100286520A1 (en) * | 2009-05-11 | 2010-11-11 | General Electric Company | Ultrasound system and method to determine mechanical properties of a target region |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
EP2525727A4 (en) | 2010-01-19 | 2017-05-03 | The Board of Regents of The University of Texas System | Apparatuses and systems for generating high-frequency shockwaves, and methods of use |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
US11865371B2 (en) | 2011-07-15 | 2024-01-09 | The Board of Regents of the University of Texas Syster | Apparatus for generating therapeutic shockwaves and applications of same |
US10835767B2 (en) | 2013-03-08 | 2020-11-17 | Board Of Regents, The University Of Texas System | Rapid pulse electrohydraulic (EH) shockwave generator apparatus and methods for medical and cosmetic treatments |
JP6396088B2 (ja) * | 2013-06-19 | 2018-09-26 | キヤノンメディカルシステムズ株式会社 | 超音波診断装置 |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US11229575B2 (en) | 2015-05-12 | 2022-01-25 | Soliton, Inc. | Methods of treating cellulite and subcutaneous adipose tissue |
KR20230078826A (ko) * | 2016-03-23 | 2023-06-02 | 솔리톤, 인코포레이티드 | 펄싱 음향파 진피 클리어링 시스템 및 방법 |
TWI742110B (zh) | 2016-07-21 | 2021-10-11 | 美商席利通公司 | 具備改良電極壽命之快速脈波電動液壓脈衝產生裝置及使用該裝置生成壓縮聲波之方法 |
CA3053796A1 (en) | 2017-02-19 | 2018-08-23 | Soliton, Inc. | Selective laser induced optical breakdown in biological medium |
CN111840584B (zh) * | 2020-07-10 | 2022-04-05 | 广州曼翔医药有限公司 | 一种脑电传感器导电液 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR989438A (fr) | 1948-10-01 | 1951-09-10 | Siemens Reiniger Werke Ag | Appareil thérapeutique à ultra-sons |
US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
US4883045A (en) | 1985-09-26 | 1989-11-28 | Erwin Theisz | Method for controlling growth of tissue cells |
JPH0341064U (ja) * | 1989-08-28 | 1991-04-19 | ||
JPH03123559A (ja) * | 1989-10-09 | 1991-05-27 | Ya Man Ltd | 超音波美容装置 |
JPH0489058A (ja) * | 1990-07-31 | 1992-03-23 | Ya Man Ltd | 接触温度を可変できる超音波美容装置 |
EP0645131A2 (en) | 1988-03-30 | 1995-03-29 | Malmros Holding, Inc. | Ultrasonic treatment of animals |
US5558092A (en) | 1995-06-06 | 1996-09-24 | Imarx Pharmaceutical Corp. | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
JPH09108288A (ja) * | 1995-10-18 | 1997-04-28 | Katsuo Soga | 美容用超音波拡散発振装置 |
JPH09154910A (ja) * | 1995-12-11 | 1997-06-17 | Dream:Kk | 超音波美容装置 |
JPH09248213A (ja) * | 1996-01-12 | 1997-09-22 | Hoomaa Ion Kenkyusho:Kk | 超音波を応用した美容・痩身器 |
JPH09276354A (ja) * | 1996-04-08 | 1997-10-28 | Ya Man Ltd | 波動美容処理装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791915A (en) * | 1986-09-29 | 1988-12-20 | Dynawave Corporation | Ultrasound therapy device |
GB2303552A (en) * | 1995-07-24 | 1997-02-26 | Gar Investment Corp | Ultrasound apparatus for non invasive cellulite reduction |
US5656016A (en) * | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
JP3041064U (ja) | 1997-03-03 | 1997-09-05 | ヤーマン株式会社 | 超音波美容処理装置 |
US5879314A (en) * | 1997-06-30 | 1999-03-09 | Cybersonics, Inc. | Transducer assembly and method for coupling ultrasonic energy to a body for thrombolysis of vascular thrombi |
US6126619A (en) * | 1997-09-02 | 2000-10-03 | Transon Llc | Multiple transducer assembly and method for coupling ultrasound energy to a body |
CA2317777C (en) * | 1998-01-08 | 2005-05-03 | Sontra Medical, Inc. | Sonophoretic enhanced transdermal transport |
-
1998
- 1998-11-09 WO PCT/JP1998/005032 patent/WO1999039677A1/ja active IP Right Grant
- 1998-11-09 CA CA002319583A patent/CA2319583C/en not_active Expired - Fee Related
- 1998-11-09 ES ES98951740T patent/ES2335826T3/es not_active Expired - Lifetime
- 1998-11-09 JP JP2000530179A patent/JP3416909B2/ja not_active Expired - Fee Related
- 1998-11-09 AU AU97629/98A patent/AU9762998A/en not_active Abandoned
- 1998-11-09 US US09/600,177 patent/US6450979B1/en not_active Expired - Fee Related
- 1998-11-09 EP EP98951740A patent/EP1060728B9/en not_active Expired - Lifetime
- 1998-11-09 CN CNB988134969A patent/CN1163211C/zh not_active Expired - Fee Related
- 1998-11-09 DE DE69841275T patent/DE69841275D1/de not_active Expired - Lifetime
- 1998-11-09 BR BRPI9815088-0A patent/BR9815088B1/pt not_active IP Right Cessation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR989438A (fr) | 1948-10-01 | 1951-09-10 | Siemens Reiniger Werke Ag | Appareil thérapeutique à ultra-sons |
US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
US4883045A (en) | 1985-09-26 | 1989-11-28 | Erwin Theisz | Method for controlling growth of tissue cells |
EP0645131A2 (en) | 1988-03-30 | 1995-03-29 | Malmros Holding, Inc. | Ultrasonic treatment of animals |
JPH0341064U (ja) * | 1989-08-28 | 1991-04-19 | ||
JPH03123559A (ja) * | 1989-10-09 | 1991-05-27 | Ya Man Ltd | 超音波美容装置 |
JPH0489058A (ja) * | 1990-07-31 | 1992-03-23 | Ya Man Ltd | 接触温度を可変できる超音波美容装置 |
US5558092A (en) | 1995-06-06 | 1996-09-24 | Imarx Pharmaceutical Corp. | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
JPH09108288A (ja) * | 1995-10-18 | 1997-04-28 | Katsuo Soga | 美容用超音波拡散発振装置 |
JPH09154910A (ja) * | 1995-12-11 | 1997-06-17 | Dream:Kk | 超音波美容装置 |
JPH09248213A (ja) * | 1996-01-12 | 1997-09-22 | Hoomaa Ion Kenkyusho:Kk | 超音波を応用した美容・痩身器 |
JPH09276354A (ja) * | 1996-04-08 | 1997-10-28 | Ya Man Ltd | 波動美容処理装置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1060728A4 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003533263A (ja) * | 1997-10-27 | 2003-11-11 | ロバート ダブリュー クリブス | 脂肪分解療法及び装置 |
KR100443201B1 (ko) * | 2001-12-10 | 2004-08-09 | 주식회사 울쏘하이텍 | 비데의 노즐장치 |
WO2004058135A1 (ja) * | 2002-12-24 | 2004-07-15 | Matsushita Electric Works, Ltd. | 超音波痩身装置 |
US10864385B2 (en) | 2004-09-24 | 2020-12-15 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
US11590370B2 (en) | 2004-09-24 | 2023-02-28 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
US11400319B2 (en) | 2004-10-06 | 2022-08-02 | Guided Therapy Systems, Llc | Methods for lifting skin tissue |
JP2019048175A (ja) * | 2004-10-06 | 2019-03-28 | ガイデッド セラピー システムズ, エル.エル.シー. | 超音波組織処理ための方法およびシステム |
JP2018108523A (ja) * | 2004-10-06 | 2018-07-12 | ガイデッド セラピー システムズ, エル.エル.シー. | 超音波組織処理ための方法およびシステム |
US11167155B2 (en) | 2004-10-06 | 2021-11-09 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
JP2019177286A (ja) * | 2004-10-06 | 2019-10-17 | ガイデッド セラピー システムズ, エル.エル.シー. | 超音波組織処理ための方法およびシステム |
US10525288B2 (en) | 2004-10-06 | 2020-01-07 | Guided Therapy Systems, Llc | System and method for noninvasive skin tightening |
US10532230B2 (en) | 2004-10-06 | 2020-01-14 | Guided Therapy Systems, Llc | Methods for face and neck lifts |
US11883688B2 (en) | 2004-10-06 | 2024-01-30 | Guided Therapy Systems, Llc | Energy based fat reduction |
US11717707B2 (en) | 2004-10-06 | 2023-08-08 | Guided Therapy Systems, Llc | System and method for noninvasive skin tightening |
US10603523B2 (en) | 2004-10-06 | 2020-03-31 | Guided Therapy Systems, Llc | Ultrasound probe for tissue treatment |
US11697033B2 (en) | 2004-10-06 | 2023-07-11 | Guided Therapy Systems, Llc | Methods for lifting skin tissue |
US10603519B2 (en) | 2004-10-06 | 2020-03-31 | Guided Therapy Systems, Llc | Energy based fat reduction |
US10610705B2 (en) | 2004-10-06 | 2020-04-07 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US10610706B2 (en) | 2004-10-06 | 2020-04-07 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US11338156B2 (en) | 2004-10-06 | 2022-05-24 | Guided Therapy Systems, Llc | Noninvasive tissue tightening system |
US11179580B2 (en) | 2004-10-06 | 2021-11-23 | Guided Therapy Systems, Llc | Energy based fat reduction |
US10888717B2 (en) | 2004-10-06 | 2021-01-12 | Guided Therapy Systems, Llc | Probe for ultrasound tissue treatment |
US10888716B2 (en) | 2004-10-06 | 2021-01-12 | Guided Therapy Systems, Llc | Energy based fat reduction |
US10960236B2 (en) | 2004-10-06 | 2021-03-30 | Guided Therapy Systems, Llc | System and method for noninvasive skin tightening |
US10960235B2 (en) | 2004-10-06 | 2021-03-30 | Guided Therapy Systems, Llc | Energy based hyperhidrosis treatment |
US11235180B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | System and method for noninvasive skin tightening |
US11235179B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | Energy based skin gland treatment |
US10888718B2 (en) | 2004-10-06 | 2021-01-12 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US11207547B2 (en) | 2004-10-06 | 2021-12-28 | Guided Therapy Systems, Llc | Probe for ultrasound tissue treatment |
US11724133B2 (en) | 2004-10-07 | 2023-08-15 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US11207548B2 (en) | 2004-10-07 | 2021-12-28 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
JP2008529580A (ja) * | 2005-02-06 | 2008-08-07 | ウルトラシェイプ エルティーディー. | 非熱式音波組織改質 |
WO2007013546A1 (ja) * | 2005-07-29 | 2007-02-01 | Kabushiki Kaisha Shunkosha | 痩身促進具 |
JP2010535060A (ja) * | 2007-07-30 | 2010-11-18 | リゼンプライム カンパニー リミテッド | むくみ治療用超音波装置およびその用途 |
US10537304B2 (en) | 2008-06-06 | 2020-01-21 | Ulthera, Inc. | Hand wand for ultrasonic cosmetic treatment and imaging |
US11123039B2 (en) | 2008-06-06 | 2021-09-21 | Ulthera, Inc. | System and method for ultrasound treatment |
US11723622B2 (en) | 2008-06-06 | 2023-08-15 | Ulthera, Inc. | Systems for ultrasound treatment |
US11969609B2 (en) | 2013-03-08 | 2024-04-30 | Ulthera, Inc. | Devices and methods for multi-focus ultrasound therapy |
US11517772B2 (en) | 2013-03-08 | 2022-12-06 | Ulthera, Inc. | Devices and methods for multi-focus ultrasound therapy |
US11351401B2 (en) | 2014-04-18 | 2022-06-07 | Ulthera, Inc. | Band transducer ultrasound therapy |
US10603521B2 (en) | 2014-04-18 | 2020-03-31 | Ulthera, Inc. | Band transducer ultrasound therapy |
JP2017077310A (ja) * | 2015-10-20 | 2017-04-27 | 株式会社ジャパンギャルズ | 超音波美容器 |
US11224895B2 (en) | 2016-01-18 | 2022-01-18 | Ulthera, Inc. | Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof |
US11241218B2 (en) | 2016-08-16 | 2022-02-08 | Ulthera, Inc. | Systems and methods for cosmetic ultrasound treatment of skin |
US11944849B2 (en) | 2018-02-20 | 2024-04-02 | Ulthera, Inc. | Systems and methods for combined cosmetic treatment of cellulite with ultrasound |
JP2020044303A (ja) * | 2018-09-14 | 2020-03-26 | 昌利 神尾 | 血管内皮機能改善法及びこれに使用する血管内皮機能改善具 |
RU2815510C1 (ru) * | 2023-05-25 | 2024-03-18 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт прикладной акустики" | Устройство для гидровиброакустического массажа |
RU2815467C1 (ru) * | 2023-05-25 | 2024-03-18 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт прикладной акустики" | Способ гидровиброакустического бесконтактного массажа |
Also Published As
Publication number | Publication date |
---|---|
DE69841275D1 (de) | 2009-12-17 |
US6450979B1 (en) | 2002-09-17 |
BR9815088A (pt) | 2000-10-24 |
BR9815088B1 (pt) | 2010-12-14 |
ES2335826T3 (es) | 2010-04-05 |
JP3416909B2 (ja) | 2003-06-16 |
EP1060728A1 (en) | 2000-12-20 |
AU9762998A (en) | 1999-08-23 |
CA2319583C (en) | 2007-08-07 |
CA2319583A1 (en) | 1999-08-12 |
CN1283982A (zh) | 2001-02-14 |
EP1060728A4 (en) | 2007-01-10 |
EP1060728B9 (en) | 2010-02-24 |
CN1163211C (zh) | 2004-08-25 |
EP1060728B1 (en) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3416909B2 (ja) | 超音波照射装置 | |
Alizadeh et al. | Review of the mechanisms and effects of noninvasive body contouring devices on cellulite and subcutaneous fat | |
JP6931877B2 (ja) | 超音波照射装置とシステム及び超音波照射方法 | |
JP4723707B2 (ja) | 痩身器具 | |
US5507790A (en) | Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism | |
US5413550A (en) | Ultrasound therapy system with automatic dose control | |
KR101605527B1 (ko) | 초음파 치료 시스템 | |
CA2783067C (en) | Heat stimulus applying apparatus | |
Luh et al. | Effects of extracorporeal shock wave-mediated transdermal local anesthetic drug delivery on rat caudal nerves | |
US20090171251A1 (en) | Ultrasound treatment of adipose tissue with vacuum feature | |
KR100556060B1 (ko) | 초음파 조사 장치 | |
US20090171250A1 (en) | Ultrasound treatment of adipose tissue with fluid injection | |
RU2289386C2 (ru) | Способ ультразвуковой физиотерапии в жидкости | |
JP2004201839A (ja) | 超音波痩身装置 | |
Halachmi et al. | Fundamentals of ultrasound sources | |
Tbakhi et al. | Design of Therapeutic Ultrasound System for Muscles Pain Treatment | |
Forrest et al. | Ultrasound treatments in degassed water | |
Ching-Chua et al. | double blind randomized controlled trial on the efficacy and safety of focused low frequency ultrasound waves versus sham treatment effect in decreasing the abdominal circumference among healthy Filipino adults | |
Varatharajullu | A double-blinded placebo-controlled investigation into the effect of therapeutic ultrasound on radial artery blood flow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98813496.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2319583 Country of ref document: CA Ref document number: 2319583 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007008542 Country of ref document: KR Ref document number: 09600177 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998951740 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998951740 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007008542 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007008542 Country of ref document: KR |